ATAC-seq在复杂疾病研究中的应用进展
收稿日期: 2019-12-10
修回日期: 2020-02-16
网络出版日期: 2020-03-06
基金资助
国际(地区)合作与交流项目资助编号(81320108016)
ATAC-seq and its applications in complex disease
Received date: 2019-12-10
Revised date: 2020-02-16
Online published: 2020-03-06
Supported by
Supported by the International Regional Cooperation and Exchange Programs No(81320108016)
染色质转座酶可及性测序(assay for transposase-accessible chromatin with high-throughput sequencing,ATAC-seq)是利用Tn5转座酶研究染色质可及性的高通量测序技术。ATAC-seq可以在全基因组范围内绘制染色质可及性图谱,揭示转录因子结合位点以及核小体的位置。在医学领域,ATAC-seq技术是研究重大疾病发病机制、药物作用机制、新药研发和生物标志物功能等的新一代有力工具。本文对ATAC-seq技术的优势及其在复杂疾病研究中的应用和前景进行了综述,以期为人类复杂疾病基因表达调控机制等相关研究的开展提供借鉴与参考。
陈敏, 张峥, 孟紫媛, 张学军 . ATAC-seq在复杂疾病研究中的应用进展[J]. 遗传, 2020 , 42(4) : 347 -353 . DOI: 10.16288/j.yczz.19-282
ATAC-seq is a high-throughput technology that defines and quantifies chromatin accessibility by analyzing Tn5 transposase enzymes. ATAC-seq is used to map chromatin accessibility genome-wide and to identify regions of transcription-factor binding and nucleosome position. As such, ATAC-seq is a new generation tool used in biomedical research to measure and articulate the pathogenesis of major diseases, to demonstrate the pharmacology of current drugs, and to guide the development of new drugs and the function of biomarkers. In this review, we summarize the current applications and advantages of ATAC-seq, and define its prospective contributions related to the regulatory mechanism of gene expression to identify and manage complex disease while elucidating and guiding future research references and strategies.
Key words： ATAC-seq; chromatin accessibility; Tn5 transposase; transcriptional level
| [1] | Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ . Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat Methods, 2013,10(12):1213-1218. |
| [2] | Buenrostro JD, Wu B, Chang HY, Greenleaf WJ. ATAC- seq: A method for assaying chromatin accessibility genome- wide. Curr Protoc Mol Biol, 2015, 109: 21.29.1-21.29.9. |
| [3] | Dirks RA, Stunnenberg HG, Marks H . Genome-wide epigenomic profiling for biomarker discovery. Clin Epigenetics, 2016,8:122. |
| [4] | Doganli C, Sandoval M, Thomas S, Hart D . Assay for Transposase-accessible chromatin with high-throughput sequencing (ATAC-Seq) protocol for zebrafish embryos. Methods Mol Biol, 2017,1507:59-66. |
| [5] | Song LY, Crawford GE. DNase-seq: a high-resolution technique for mapping active gene regulatory elements across the genome from mammalian cells. Cold Spring Harb Protoc, 2010, 2010(2): pdb prot5384. |
| [6] | Han JL, Li ZJ, Wang K . Progress on genome-wide identification and analysis of transcriptional regulatory elements based on open-chromatin signatures. J Fujian Agric Fore Uni (Nat Sci Edi), 2017,46(1):1-8. |
| [6] | 韩金磊, 李占杰, 王凯 . 基于开放染色质的全基因组水平转录调控元件的研究方法与进展. 福建农林大学学报: 自然科学版, 2017,46(1):1-8. |
| [7] | Grbesa I, Tannenbaum M, Sarusi-Portuguez A, Schwartz M, Hakim O. Mapping genome-wide accessible chromatin in primary Human T Lymphocytes by ATAC-Seq. J Vis Exp, 2017, (129): doi: 10.3791/56313. |
| [8] | Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, Jaffe ES . The 2018 update of the WHO- EORTC classification for primary cutaneous lymphomas. Blood, 2019,133(16):1703-1714. |
| [9] | New M, Olzscha H, La Thangue NB . HDAC inhibitor- based therapies: Can we interpret the code? Mol Oncol, 2012,6(6):637-656. |
| [10] | Qu K, Zaba LC, Satpathy AT, Giresi PG, Li R, Jin YH, Armstrong R, Jin C, Schmitt N, Rahbar Z, Ueno H, Greenleaf WJ, Kim YH, Chang HY, . Chromatin accessibility landscape of cutaneous T cell lymphoma and dynamic response to HDAC inhibitors. Cancer Cell, 2017, 32(1): 27-41. e4. |
| [11] | Wu J, Wood GS . Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma. Arch. Dermatol, 2011,147(4):443-449. |
| [12] | Zhang TH, Inesta-Vaquera F, Niepel M, Zhang JM, Ficarro SB, Machleidt T, Xie T, Marto JA, Kim N, Sim T, Laughlin JD, Park H, LoGrasso PV, Patricelli M, Nomanbhoy TK, Sorger PK, Alessi DR, Gray NS . Discovery of potent and selective covalent inhibitors of JNK. Chem Biol, 2012,19(1):140-154. |
| [13] | Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West N, Cameron MJ, Schwartz B, Heightman TD, La Thangue N, French CA, Wiest O, Kung AL, Knapp S, Bradner JE . Selective inhibition of BET bromodomains. Nature, 2010,468(7327):1067-1073. |
| [14] | Satpathy AT, Saligrama N, Buenrostro JD, Wei Y, Wu B, Rubin AJ, Granja JM, Lareau CA, Li R, Qi Y, Parker KR, Mumbach MR, Serratelli WS, Gennert DG, Schep AN, Corces MR, Khodadoust MS, Kim YH, Khavari PA, Greenleaf WJ, Davis MM, Chang HY . Transcript-indexed ATAC-seq for precision immune profiling. Nat Med, 2018,24(5):580-590. |
| [15] | Rendeiro AF, Schmidl C, Strefford JC, Walewska R, Davis Z, Farlik M, Oscier D, Bock C . Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype- specific epigenome signatures and transcription regulatory networks. Nat Commun, 2016,7:11938. |
| [16] | Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marcé S, López-Guillermo A, Campo E, Montserrat E . ZAP-70 Expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med, 2003,348(18):1764-1775. |
| [17] | Ott CJ, Federation AJ, Schwartz LS, Kasar S, Klitgaard JL, Lenci R, Li Q, Lawlor M, Fernandes SM, Souza A, Polaski D, Gadi D, Freedman ML, Brown JR, Bradner JE . Enhancer architecture and essential core regulatory circuitry of chronic lymphocytic leukemia. Cancer Cell, 2018,34(6):982-995. |
| [18] | Dechassa ML, Tryndyak V, de Conti A, Xiao W, Beland FA, Pogribny IP . Identification of chromatin-accessible domains in non-alcoholic steatohepatitis-derived heaptocellular carcinoma. Mol Carcinog, 2018,57(8):978-987. |
| [19] | Britton E, Rogerson C, Mehta S, Li Y, Li X, Fitzgerald RC, Ang YS, Sharrocks AD . Open chromatin profiling identifies AP1 as a transcriptional regulator in oesophageal adenocarcinoma. PLoS Genetics, 2017,13(8):e1006879. |
| [20] | Wang ZF, Tu KL, Xia L, Luo K, Luo WX, Tang J, Lu KY, Hu XL, He YJ, Qiao WL, Zhou YZ, Zhang J, Cao F, Dai SP, Tian PW, Wang Y, Liu LX, Che GW, Zhou QH, Xie D, Li WM . The open chromatin landscape of non-small cell lung carcinoma. Cancer Res, 2019,79(19):4840-4854. |
| [21] | Zhu L, Yin ZJ, Ju BM, Zhang J, Wang YH, Lv XH, Hao ZM, He L . Altered frequencies of memory B cells in new-onset systemic lupus erythematosus patients. Clin Rheumatol, 2018,37(1):205-212. |
| [22] | Vaughn SE, Kottyan LC, Munroe ME, Harley JB . Genetic susceptibility to lupus: the biological basis of genetic risk found in B cell signaling pathways. J Leukoc Biol, 2012,92(3):577-591. |
| [23] | Farh KK, Marson A, Zhu J, Kleinewietfeld M, Housley WJ, Beik S, Shoresh N, Whitton H, Ryan RJ, Shishkin AA, Hatan M, Carrasco-Alfonso MJ, Mayer D, Luckey CJ, Patsopoulos NA, De Jager PL, Kuchroo VK, Epstein CB, Daly MJ, Hafler DA, Bernstein BE . Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature, 2015,518(7539):337-343. |
| [24] | Scharer CD, Blalock EL, Barwick BG, Haines RR, Wei C, Sanz I, Boss JM . ATAC-seq on biobanked specimens defines a unique chromatin accessibility structure in na?ve SLE B cells. Sci Rep, 2016,6(1):27030. |
| [25] | Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB . Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-α in lupus patients in vivo. J Immunol, 2009,182(1):34-38. |
| [26] | Gensterblum E, Renauer P, Coit P, Strickland FM, Kilian NC, Miller S, Ognenovski M, Wren JD, Tsou PS, Lewis EE, Maksimowicz-McKinnon K, McCune WJ, Richardson BC, Sawalha AH, . CD4+CD28+KIR+CD11a hi T cells correlate with disease activity and are characterized by a pro-inflammatory epigenetic and transcriptional profile in lupus patients . J Autoimmun, 2018,86:19-28. |
| [27] | Bacos K, Gillberg L, Volkov P, Olsson AH, Hansen T, Pedersen O, Gjesing AP, Eiberg H, Tuomi T, Almgren P, Groop L, Eliasson L, Vaag A, Dayeh T, Ling C . Blood-based biomarkers of age-associated epigenetic changes in human islets associate with insulin secretion and diabetes. Nat Commun, 2016,7:11089. |
| [28] | Varshney A, Scott LJ, Welch RP, Erdos MR, Chines PS, Narisu N, Albanus RD, Orchard P, Wolford BN, Kursawe R, Vadlamudi S, Cannon ME, Didion JP, Hensley J, Kirilusha A, NISC Comparative Sequencing Program, Bonnycastle LL, Taylor DL, Watanabe R, Mohlke KL, Boehnke M, Collins FS, Parker SC, Stitzel ML . Genetic regulatory signatures underlying islet gene expression and type 2 diabetes. Proc Natl Acad Sci USA, 2017,114(9):2301-2306. |
| [29] | Bysani M, Agren R, Daveg?rdh C, Volkov P, R?nn T, Unneberg P, Bacos K, Ling C . ATAC-seq reveals alterations in open chromatin in pancreatic islets from subjects with type 2 diabetes. Sci Rep, 2019,9(1):7785. |
| [30] | Ackermann AM, Wang Z, Schug J, Naji A, Kaestner KH . Integration of ATAC-seq and RNA-seq identifies human alpha cell and beta cell signature genes. Mol Metab, 2016,5(3):233-244. |
| [31] | Greenwald WW, Chiou J, Yan J, Qiu Y, Dai N, Wang A, Nariai N, Aylward A, Han JY, Kadakia N, Regue L, Okino ML, Drees F, Kramer D, Vinckier N, Minichiello L, Gorkin D, Avruch J, Frazer KA, Sander M, Ren B, Gaulton KJ . Pancreatic islet chromatin accessibility and conformation reveals distal enhancer networks of type 2 diabetes risk. Nat Commun, 2019,10(1):2078. |
| [32] | Findlay DM, Kuliwaba JS . Bone-cartilage crosstalk: a conversation for understanding osteoarthritis. Bone Res, 2016,4:16028. |
| [33] | Liu Y, Chang JC, Hon CC, Fukui N, Tanaka N, Zhang Z, Lee MTM, Minoda A . Chromatin accessibility landscape of articular knee cartilage reveals aberrant enhancer regulation in osteoarthritis. Sci Rep, 2018,8(1):15499. |
| [34] | Baird DA, Evans DS, Kamanu FK, Gregory JS, Saunders FR, Giuraniuc CV, Barr RJ, Aspden RM, Jenkins D, Kiel DP, Orwoll ES, Cummings SR, Lane NE, Mullin BH, Williams FM, Richards JB, Wilson SG, Spector TD, Faber BG, Lawlor DA, Grundberg E, Ohlsson C, Pettersson- Kymmer U, Capellini TD, Richard D, Beck TJ, Evans DM, Paternoster L, Karasik D, Tobias JH . Identification of novel loci associated with hip shape: a meta-analysis of genome-wide association studies. J Bone Miner Res, 2019,34(2):241-251. |
| [35] | Corces MR, Granja JM, Shams S, Louie BH, Seoane JA, Zhou W, Silva TC, Groeneveld C, Wong CK, Cho SW, Satpathy AT, Mumbach MR, Hoadley KA, Robertson AG, Sheffield NC, Felau I, Castro MAA, Berman BP, Staudt LM, Zenklusen JC, Laird PW, Curtis C, Greenleaf WJ, Chang HY . The chromatin accessibility landscape of primary human cancers. Science, 2018,362(6413). |
| [36] | Tak YG, Farnham PJ . Making sense of GWAS: using epigenomics and genome engineering to understand the functional relevance of SNPs in non-coding regions of the human genome. Epigenetics Chromatin, 2015,8(1):57. |
| [37] | Wang J, Zibetti C, Shang P, Sripathi SR, Zhang PW, Cano M, Hoang T, Xia SL, Ji HK, Merbs SL, Zack DJ, Handa JT, Sinha D, Blackshaw S, Qian J . ATAC-Seq analysis reveals a widespread decrease of chromatin accessibility in age-related macular degeneration. Nat Commun, 2018,9(1):1364. |
| [38] | Sun YY, Miao N, Sun T . Detect accessible chromatin using ATAC-sequencing, from principle to applications. Hereditas, 2019,156:29. |
| [39] | Shen S, Qu YC, Zhang J . The application of next generation sequencing on epigenetic study. Hereditas (Beijing), 2014,36(3):256-275. |
| [39] | 沈圣, 屈彦纯, 张军 . 下一代测序技术在表观遗传学研究中的重要应用及进展. 遗传, 2014,36(3):256-275. |
| [40] | Hendrickson DG, Soifer I, Wranik BJ, Botstein D, Scott McIsaac R,. Simultaneous profiling of DNA accessibility and gene expression dynamics with ATAC-Seq and RNA-Seq. Methods Mol Biol, 2018,1819:317-333. |
/
| 〈 |
|
〉 |
www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:
